Selegiline Orally Disintegrating Tablets in Patients With Parkinson Disease and "Wearing Off" Symptoms

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Clinical neuropharmacology

• Publication date

  2007-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/WNF.0b013e3180616570PMID 17909308
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Selegiline slows the progression of the symptoms of Parkinson disease

  2006cited by this paper
• Practice Parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

  2006cited by this paper
• Long‐term efficacy and safety of pramipexole in advanced Parkinson's disease: Results from a European multicenter trial

  2005cited by this paper
• Identification of motor and nonmotor wearing‐off in Parkinson's disease: Comparison of a patient questionnaire versus a clinician assessment

  2005cited by this paper
• Levodopa and the progression of Parkinson's disease.

  2004cited by this paper
• Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: A 3‐month, randomized, placebo‐controlled study

  2004cited by this paper
• A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition

  2003cited by this paper
• A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition

  2003cited by this paper
• Clinical assessment of dysphagia in early phases of Parkinson's disease

  2002cited by this paper
• The influence of metabolism on the MAO-B inhibitory potency of selegiline.

  2002cited by this paper
• Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline

  2001cited by this paper
• Effect of selegiline on dopamine concentration in the striatum of a primate.

  1999cited by this paper
• Evolution of motor fluctuations in Parkinson's disease: A longitudinal study over 6 years

  1999cited by this paper
• Swallowing difficulty in Parkinson's disease.

  1997cited by this paper
• Metabolism of selegiline in humans. Identification, excretion, and stereochemistry of urine metabolites.

  1997cited by this paper
• L‐Deprenyl (Selegiline) Added to Sinemet CR in the Management of Parkinson's Disease Patients With Motor Response Fluctuations

  1991cited by this paper
• Long‐term efficacy and safety of deprenyl (selegiline) in advanced Parkinson's disease

  1989cited by this paper
• Deprenyl as symptomatic therapy in Parkinson's disease.

  1988cited by this paper

• Treatment strategies for motor fluctuations in Parkinson’s disease: a systematic review of efficacy, functionality, and drug accessibility with a focus on Latin America

  2025cites this paper
• Update on Treatments for Parkinson's Disease Motor Fluctuations – An International Parkinson and Movement Disorder Society Evidence‐Based Medicine Review

  2025cites this paper
• Efficacy and safety of adjunctive oral therapy in Parkinson’s disease with motor complications: a systematic review and network meta-analysis

  2024cites this paper
• Effects and Safety of Monoamine Oxidase-B Inhibitors for Early Parkinson’s Disease: A Network Meta-Analysis

  2024cites this paper
• Parkinson’s disease updates: Addressing the pathophysiology, risk factors, genetics, diagnosis, along with the medical and surgical treatment

  2023cites this paper
• Comparative efficacy and safety of adjunctive drugs to levodopa for fluctuating Parkinson’s disease - network meta-analysis

  2023cites this paper
• Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson's disease: a network meta‐analysis of randomized controlled trials

  2022cites this paper
• Medical Management and Prevention of Motor Complications in Parkinson’s Disease

  2020cites this paper
• Clinimetrics of the 9- and 19-Item Wearing-Off Questionnaire: A Systematic Review

  2018cites this paper
• Antidepressants versus placebo in major depression: an overview

  2015cites this paper
• How to prove that your therapy is effective, even when it is not: a guideline

  2015cites this paper
• Evidence-based treatment of Parkinson's disease

  2015cites this paper
• Pharmacological treatment of Parkinson disease: a review.

  2014cites this paper
• Pharmacological Strategies for the Management of Levodopa-Induced Dyskinesia in Patients with Parkinson’s Disease

  2014cites this paper
• Review: management of Parkinson’s disease

  2013cites this paper
• Monoamine oxidase inhibitors

  2013cites this paper
• Oral Disintegrating Tablets A Current Review

  2013cites this paper
• The pharmacokinetic evaluation of selegiline ODT for the treatment of Parkinson's disease

  2013influential citation
• Summary of the recommendations of the EFNS/MDS‐ES review on therapeutic management of Parkinson's disease

  2013cites this paper
• National surveys: a way to manage treatment strategies in Parkinson’s disease? Pharmaceutical prescribing patterns and patient experiences of symptom control and their impact on disease

  2013cites this paper
• Effects of monoamine oxidase Type B inhibitors on motor and non-motor symptoms in Parkinson's disease: A systematic comparison of rasagiline and selegiline

  2012cites this paper
• Selegiline: A Reappraisal of Its Role in Parkinson Disease

  2012cites this paper
• Parkinson's Disease Therapeutics: New Developments and Challenges Since the Introduction of Levodopa

  2012cites this paper
• [Parkinson's disease: current standards in diagnostics and therapy].

  2012cites this paper
• Morbus Parkinson: Aktuelle Standards in Diagnostik und Therapie

  2012cites this paper
• The anti-Parkinsonian drug selegiline delays the nucleation phase of α-synuclein aggregation leading to the formation of nontoxic species.

  2011cites this paper
• The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease

  2011cites this paper
• Tolerability and efficacy of switching from oral selegiline to Zydis selegiline in patients with Parkinson's disease.

  2011cites this paper
• Strategies for Parkinson’s disease care: prevention and management of motor fluctuations

  2011cites this paper
• The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the non‐motor symptoms of Parkinson's disease

  2011cites this paper
• Treatments for Parkinson disease—past achievements and current clinical needs

  2009cites this paper
• The scientific and clinical basis for the treatment of Parkinson disease (2009)

  2009cites this paper
• MAO-B inhibitor know-how

  2009cites this paper
• New drug delivery strategies for improved Parkinson's disease therapy.

  2009cites this paper
• Minority enrollment in Parkinson's disease clinical trials.

  2009cites this paper
• Newdrugdeliverystrategies forimprovedParkinson'sdisease therapy

  2009cites this paper
• New drug delivery strategies for improved Parkinson's disease therapy

  2009cites this paper
• Medical management of motor fluctuations.

  2008cites this paper
• The increasing role of monoamine oxidase type B inhibitors in Parkinson's disease therapy.

  2008cites this paper
• The increasing role of monoamine oxidase type B inhibitors in Parkinson's disease therapy

  2008cites this paper
• Orally disintegrating selegiline for the treatment of Parkinson's disease

  2008cites this paper
• Current status of symptomatic medical therapy in Parkinson’s disease

  2008cites this paper
• Is the problem of a high placebo response unique to antidepressant trials?

  2008cites this paper
• A perspective on adjunctive therapy for Parkinson disease with monoamine oxidase-B inhibition.

  2007cites this paper